Royalty Pharma Q2 Portfolio Receipts Rise 6%, Full-Year Guidance Raised to $3.4–$3.5 Billion
RPRX sits 69% above its 52-week low of $34.081.
Summary
Royalty Pharma reported Q2 2026 Portfolio Receipts of $773 million, up 6% year-over-year, and raised full-year guidance to $3.4–$3.5 billion. GAAP net income was impacted by non-cash charges, but underlying cash generation remains strong.
Key Events · Earnings and Guidance · RPRX
-
Portfolio Receipts Up 6%
Q2 2026 Portfolio Receipts reached $773 million, a 6% increase from $727 million in Q2 2025, driven by strong growth in Tremfya, Voranigo, and Evrysdi.
-
Full-Year Guidance Raised
Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, up from the prior range of $3.325–$3.45 billion, reflecting confidence in the royalty portfolio.
-
Non-Cash Provision Expense
Q2 2026 GAAP results included a $268 million non-cash provision expense, primarily from Adstiladrin and the cystic fibrosis franchise, and a $69 million impairment on Tazverik.
-
Liquidity and Capital Deployment
Cash and equivalents stood at $812 million as of June 30, 2026. A new $1.8 billion revolving credit facility was secured, and $95.6 million was spent on share repurchases in H1 2026.
Analysis · RPRX · Life Sciences
Royalty Pharma delivered a solid quarter with Portfolio Receipts up 6% to $773 million, driven by strong performances from Tremfya, Voranigo, and Evrysdi. The company raised its full-year 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, signaling confidence in its royalty portfolio. However, GAAP net income was pressured by a $268 million non-cash provision expense, largely from Adstiladrin and the cystic fibrosis franchise, and a $69 million impairment on Tazverik. The balance sheet remains robust with $812 million in cash and a new $1.8 billion revolving credit facility, providing ample liquidity for further royalty acquisitions. The ongoing dispute with Vertex over Alyftrek royalties adds uncertainty, but the raised guidance and active capital deployment underscore management's positive outlook.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RPRX was trading at $57.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.1B. The 52-week trading range was $34.08 to $60.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.